Clinical Trial Update: L-Carnitine as an Osmo-metabolic Agent for Peritoneal Dialysis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating L-Carnitine as an osmo-metabolic agent for peritoneal dialysis in end-stage renal disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• L-carnitine (L-carnitine)

Snippet

Sponsor: Iperboreal Pharma Srl | Conditions: End-Stage Renal Disease | Phase 2 | Status: COMPLETED